You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

46 Results
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Nab-Paclitaxel - Hypersensitivity Reactions to Taxanes
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
nab-PACLitaxel
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    niLOtinib - Chronic phase Ph+ CML, with specific criteria
Exceptional Access Program
    niLOtinib - Accelerated phase Ph+ CML with documented resistance or intolerance to imatinib therapy, with specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
niLOtinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2023
Cancer facts
Sep 2019
Drug
Other Name(s): Opdualag™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Feb 2025
Drug
Other Name(s): Opdivo®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Oct 2024
Drug
Other Name(s): Atriance®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Apr 2024
Drug
Other Name(s): Tasigna®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 2023
Drug
Other Name(s): Zejula
Quick Link(s):
Drug Monograph, Patient Info Sheet
Mar 2025
Drug
Other Name(s): Abraxane®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 2024
Drug
Other Name(s): Anandron® ()
Quick Link(s):
Drug Monograph, Patient Info Sheet
Sep 2018

Pages